期刊
PHARMACOGENETICS AND GENOMICS
卷 17, 期 10, 页码 885-890出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FPC.0b013e3282ef5cd1
关键词
efavirenz; gene deletion; pharmacogenetics; unequal crossover
Objective To evaluate the possibility of copy number variation (CNV) of CYP2B6. Methods We investigated CNV in 226 HIV-1-infected individuals by quantitative PCR. Identification of a candidate CNV prompted characterization of the size of deletion by assessment of absence of exons, mapping of the recombination site by sequencing, and by southern blot. The functional consequences of CNV were assessed in silico (predicted protein), and in vivo, by evaluation of plasma drug levels of the CYP2B6 substrate efavirenz. Results Analyses identified one white individual carrying a heterozygous deletion of exons 1-4 of CYP2B6. We identified a similar to 68 kb deletion between CYP2B7 and CYP2B6, and mapped the crossover to a homologous region in intron 4 of both genes. The new hybrid allele, named CYP2B6*29, carries two amino acid substitutions, Q172H and M198T, previously associated with impaired enzyme function. Consistent with the functional prediction, the average of efavirenz area under the curve values of the patient was mean +/- SD, 81.64 +/- 23.62, versus 4775 +/- 19.73 mu g h/ml for individuals with an extensive metabolizer phenotype. Conclusion CYP2B6*29 represents a new mechanism of genetic variation at the CYP2B6 locus, underscoring the highly polymorphic nature of this isoenzyme.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据